• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

    7/13/26 4:45:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email

    Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5.

    Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713940133/en/

    Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility.

    Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility.

    Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM which is clinically proven to lower A1C and increase time in range6-10, Dexcom G7 15 Day sets a new standard in CGM technology that’s easy to use, painless to insert* and requires fewer sensor changes per month.

    Diabetes is a complex and challenging condition that affects more than four million Canadians11 and requires around-the-clock management of glucose levels and decision‑making to manage safely.

    "Small improvements can make a meaningful difference for people living with diabetes. Dexcom G7 15 Day reflects our ongoing commitment to simpler, more seamless diabetes management," said André Côté, Vice President and General Manager, Dexcom Canada.

    New with Dexcom G7 15 Day:

    • Longest lasting CGM system with 15.5 days of wear.5
    • Best-in-class accuracy with an overall MARD of 8.0%.1-4
    • Easier glucose management with fewer monthly sensor changes and reduced waste.

    Dexcom G7 features included with Dexcom G7 15 Day:

    • The only waterproof† CGMs available
    • Direct to Apple Watch‡ connectivity, so you can leave your phone behind and still see your glucose numbers.
    • 12-hour grace period to replace finished sensors for a more seamless transition between sessions.
    • Innovative and simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends and statistics for meaningful conversations with your healthcare provider.§
    • Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind. ||,12
    • Customizable alert settings for improved discretion and personalized diabetes management.

    While authorized by Health Canada, Dexcom G7 15 Day is not yet available for purchase. André Côté shares, "Our focus is on ensuring that when the product becomes available, Canadians living with diabetes and their healthcare providers have the support, education, and experience they need from day one. We look forward to sharing more details as we move closer to availability."

    Visit Dexcom.com to get started with Dexcom G7 today, and register your details to opt in and receive information when Dexcom G7 15 Day becomes available.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

    Category: IR

    ____________________

    * 96% of patients reported mild/no pain.

    † The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed.

    ‡ Smart devices sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch.

    § An internet connection is required for users to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity.

    || Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions.

    1 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502.

    2 Dexcom G7 15 Day User Guide.

    3 FreeStyle Libre 3+ User Manual.

    4 Medtronic Guardian Sensor User Guide.

    5 Dexcom, Data on File, 2025.

    6 Beck RW, et al. JAMA. 2017;317(4):371-378.

    7 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.

    8 Martens T, et al. JAMA. 2021;325(22):2262-2272.

    9 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.

    10 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147.

    11 Diabetes Canada. Diabetes in Canada. https://www.diabetes.ca/advocacy-policies/advocacy-reports/national-and-provincial-backgrounders/diabetes-in-canada. Accessed May 7, 2026.

    12 Polonsky WH, Fortmann AL. Diabetes Technol Ther. 2021;23(3):195-202.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260713940133/en/

    Investor Contact:

    Sean Christensen

    sean.christensen@dexcom.com

    Media Contact:

    Kyla Rudyk-de Leth

    Veritas Communications

    rudyk@veritasinc.com

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    6/23/2026$86.00Buy
    Deutsche Bank
    5/12/2026$77.00Buy
    The Benchmark Company
    3/24/2026$90.00In-line → Outperform
    Evercore ISI
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    7/16/26 5:06:12 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    7/7/26 4:09:41 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/17/26 4:32:31 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    DexCom Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DEXCOM INC (0001093557) (Filer)

    5/28/26 5:15:16 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DexCom Inc.

    SD - DEXCOM INC (0001093557) (Filer)

    5/28/26 4:10:18 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    5/21/26 5:05:11 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

    Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5. Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713940133/en/Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility. D

    7/13/26 4:45:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the star

    7/9/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Further Advances Vision of Glucose Biosensing for All

    At Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States.The company also announced details regarding the rollout of its fully reimagined Stelo app experience launching in July in the US, helping make glucose insights more approachable and actionable for people seeking better health.Expanded international availability of Stelo is also planned for the United Kingdom, Australia, New Zealand and South Korea starting later this year and will continue into 2027.DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of mil

    6/23/26 9:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on Dexcom with a new price target

    Deutsche Bank initiated coverage of Dexcom with a rating of Buy and set a new price target of $86.00

    6/23/26 7:56:39 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    The Benchmark Company initiated coverage on Dexcom with a new price target

    The Benchmark Company initiated coverage of Dexcom with a rating of Buy and set a new price target of $77.00

    5/12/26 8:31:19 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00

    3/24/26 9:07:04 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the star

    7/9/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports First Quarter 2026 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025. F

    4/30/26 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s

    4/2/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

    Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap Initiatives Follow Constructive Engagement with Elliott Management DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. "We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosen

    5/14/26 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Rick Osterloh to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und

    2/26/26 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care